首页|期刊导航|International Journal of Ophthalmology(English edition)|Targeting ferroptosis in ocular diseases:mechanisms,clinical implications,and therapeutic horizons

Targeting ferroptosis in ocular diseases:mechanisms,clinical implications,and therapeutic horizonsOA

中文摘要

●Ferroptosis,an iron-dependent form of regulated cell death driven by lipid peroxidation,has been increasingly implicated in selected ocular diseases,although its causal relevance varies across disease entities.The retina and retinal pigment epithelium are biologically susceptible to ferroptosis-related injury because of their high oxygen demand,abundant polyunsaturated lipids,mitochondrial activity,light exposure,and tightly regulated iron handling.This review summarizes core mechanisms of ocular ferroptosis,including iron uptake and export,glutathione-glutathione peroxidase 4(GPX4)-dependent antioxidant defense,lipid peroxidation,mitochondrial dysfunction,neuroinflammation,and blood-retina barrier disruption.We discuss evidence from major degenerative,vascular,ischemic,hereditary,infectious,and immune-mediated retinal diseases,with particular attention to glaucoma,agerelated macular degeneration,diabetic retinopathy,ocular toxoplasmosis,uveitis,retinal vasculitis,and inflammatory chorioretinopathy.We also evaluate ferroptosis-targeted therapeutic strategies,proposed operational criteria for defining ferroptosis in retinal disease,and candidate structural,functional,biochemical,and imaging endpoints for future translational studies.Current evidence supports ferroptosis as a context-dependent contributor to retinal injury rather than a uniform pathogenic mechanism.Future studies should integrate cell-type-resolved biomarkers,lipidomic and imaging readouts,functional rescue experiments,and clinically meaningful visual outcomes to clarify when ferroptosis modulation may support vision preservation.

Nai-Yuan Zhang;Hui-Qian Kong;Yu-Qiao Liao;Yi-Ji Pan;Wei Sun;Lei Xi;Hong-Hua Yu;Yun-Hong Shi

Guangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,China Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong,Shantou 515000,Guangdong Province,China Fifth Clinical Institute of Shantou University Medical College,Shantou 515041,Guangdong Province,ChinaGuangdong Eye Institute,Department of Ophthalmology,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,Guangdong Province,China

医药卫生

ferroptosislipid peroxidationretinal pigment epitheliumiron chelationglaucomaage-related macular degenerationdiabetic retinopathyischemic fundus disorders

《International Journal of Ophthalmology(English edition)》 2026 (9)

P.1858-1877,20

Supported by National Natural Science Foundation of China(No.U24A20707,No.82171075)Guangdong Basic and Applied Basic Research Foundation(No.2023B1515120028)Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients with Persistent Diabetic Macular Edema(No.2024-29).

10.18240/ijo.2026.09.21

评论